-
Bronchiectasis vs. COPD vs. NTM/MAC: Key Differences, Symptoms & Treatment
Introduction When it comes to chronic lung diseases, conditions like bronchiectasis, chronic obstructive pulmonary disease (COPD), and nontuberculous mycobacteria (NTM)/Mycobacterium avium complex (MAC) infections often cause confusion due to overlapping symptoms such as chronic cough, shortness of breath, and mucus production. However, each condition has distinct causes, diagnostic methods, and… Read more ⇢
-
Ocular Melanoma Information and Resources: Causes, Insights, and Treatment Options
Ocular melanoma is the most common primary intraocular malignancy in adults, originating in the choroid, the vascular layer of the eye. Though rare, it is a serious condition that requires timely diagnosis and treatment. Understanding its causes, symptoms, and available treatment options is essential for patients and caregivers navigating this… Read more ⇢
-
Creating an Inclusive Future: Addressing the Unique Needs of LGBTQ+ Participants in Clinical Research
Healthcare is a deeply personal journey, yet for too long, many communities, including the LGBTQ+ population, have faced systemic barriers that limit their access to proper care. When it comes to clinical research, this is even more noticeable. Historically, LGBTQ+ patients have been overlooked, misunderstood, or misrepresented in studies, leaving… Read more ⇢
-
Shining a Light on Rare Disease Day: Advocating for Awareness and Access
Every year on the last day of February, (which is sometimes on Leapcure’s birthday) the global community comes together to recognize Rare Disease Day, a vital initiative that raises awareness for the approximately 300 million people worldwide living with a rare disease. With more than 7,000 rare diseases identified, many… Read more ⇢
-
Why Time is the Most Expensive Resource in Clinical Trials—And How to Make Every Second Count
The High Cost of Delayed Clinical Trials In clinical research, time isn’t just money—it’s the most expensive resource. Every day a clinical trial is delayed, sponsors face skyrocketing costs, lost revenue opportunities, and prolonged patient suffering. According to a study by the Tufts Center for the Study of Drug Development,… Read more ⇢
-
Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Trials and Understanding the Future of Treatment
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, autoimmune condition that primarily affects the optic nerves and spinal cord. It is often mistaken for multiple sclerosis (MS) due to overlapping symptoms, but it has a distinct pathophysiology, primarily driven by antibodies against the aquaporin-4 (AQP4) protein. As our understanding of… Read more ⇢
-
FDA Removed Diversity Action Plan Guidance, but Its Purpose is as Strong as Ever
As of February 11th, 2025, FDA Guidance on Diversity Action Plans has been restored by court order, but now includes a memo from the Trump Administration to disregard information that it might pertain. In the dynamic landscape of clinical research, the U.S. Food and Drug Administration (FDA) recently made headlines… Read more ⇢
-
Understanding Eligibility and Common Challenges in IPF Clinical Trials
Eligibility criteria in IPF clinical trials ensure participant safety and reliable results. Common reasons for disqualification include medication use, exclusionary medical conditions, and lack of a confirmed diagnosis. Understanding these criteria helps patients navigate the trial process and explore available options to improve their outcomes and manage expectations. Read more ⇢
-
Breaking Barriers: Tackling Underrepresentation of Rural Communities in Clinical Trials
Clinical trials transform healthcare, but for many rural communities, access remains out of reach. While ongoing efforts aim to bridge these gaps, more work is needed to ensure equitable opportunities for every patient, regardless of location. Many rural communities face challenges such as geographic isolation, limited access, and lack of… Read more ⇢
Where Clinical Trial Community Leap Together
Weekly candid conversations with people shaping the future of clinical research.
